Objectives: To investigate the risk factors for plastic bronchitis (PB) in children with macrolide-unresponsive pneumonia (MUMPP) and to establish a nomogram prediction model.
Methods: A retrospective analysis was conducted on 178 children with MUMPP who underwent bronchoscopy from January to December 2023. According to the presence or absence of PB, the children were divided into a PB group (49 children) and a non-PB group (129 children). The predictive factors for the development of PB in children with MUMPP were analyzed, and a nomogram prediction model was established. The model was assessed in terms of discriminatory ability, accuracy, and clinical effectiveness.
Results: The multivariate logistic regression analysis showed that older age and higher levels of lactate dehydrogenase and fibrinogen were closely associated with the development of PB in children with MUMPP (<0.05). A nomogram model established based on these factors had an area under the receiver operating characteristic curve of 0.733 (95%: 0.651-0.816, <0.001) and showed a good discriminatory ability. The Hosmer-Lemeshow goodness-of-fit test indicated that the predictive model had a good degree of fit (>0.05), and the decision curve analysis showed that the model had a good clinical application value.
Conclusions: The risk nomogram model established based on age and lactate dehydrogenase and fibrinogen levels has good discriminatory ability, accuracy, and predictive efficacy for predicting the development of PB in children with MUMPP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7499/j.issn.1008-8830.2408073 | DOI Listing |
Zhongguo Dang Dai Er Ke Za Zhi
January 2025
Department of Pediatrics, Provincial Hospital Affiliated to Fuzhou University/Fujian Provincial Hospital, Fuzhou 350001, China.
Objectives: To investigate the risk factors for plastic bronchitis (PB) in children with macrolide-unresponsive pneumonia (MUMPP) and to establish a nomogram prediction model.
Methods: A retrospective analysis was conducted on 178 children with MUMPP who underwent bronchoscopy from January to December 2023. According to the presence or absence of PB, the children were divided into a PB group (49 children) and a non-PB group (129 children).
Zhongguo Dang Dai Er Ke Za Zhi
December 2024
Department of Pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Objectives: To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive pneumonia (MUMPP) in children.
Methods: A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC.
Front Pediatr
December 2024
Department of Pediatrics, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Introduction: Macrolide-unresponsive pneumonia (MUMPP) cases have been rapidly increasing. The primary reason for this increased incidence is the pathogen's acquisition of resistance through mutations in 23S rRNA genes. Due to the unfeasibility of testing for macrolide susceptibility at the time of admission, this study aimed to assess the clinical features of pediatric MUMPP, using insights from laboratory tests and patterns of chest radiographic resolution.
View Article and Find Full Text PDFInfect Drug Resist
July 2024
Department of Respiratory Medicine, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Big Data Engineering Center, Children's Hospital of Chongqing Medical University, Chongqing, 400014, People's Republic of China.
Objective: (MP) is highly resistant to macrolides in China. However, macrolides still exhibit clinical effectiveness in some macrolide-resistant patients. We tend to explore azithromycin effectiveness in pneumonia (MPP) children with A2063/2064G mutation.
View Article and Find Full Text PDFJ Inflamm Res
November 2022
Department of Pediatrics, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.
Objective: The individualized prediction of treatment regimens of macrolide-unresponsive pneumonia (MUMPP) is scarce. The aim of this study was, therefore, to evaluate the relevant data of patients and construct a nomogram for identifying refractory pneumonia (RMPP) among children continued to be treated with macrolide after the confirmation of MUMPP, providing a reference for the choice of treatment regimen.
Methods: We performed a retrospective study involving 162 children who continued to be treated with macrolide (azithromycin) after the confirmation of MUMPP without antibiotic changes between January 2020 and January 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!